NKGen Biotech, Inc. Nyse

NKGN

US65488A1016

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
1.34 ^USD	-6.29%		-18.29%	-83.86%

Apr. 29	Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	CI
Apr. 29	NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	CI

Graf Acquisition Corp. IV Announces Resignation of Sterling Cross as Chief Financial Officer

April 17, 2023 at 06:02 am EDT

Graf Acquisition Corp. IV announced that on April 13, 2023, Sterling Cross, Graf's Chief Financial Officer, notified Graf of his intention to resign from his position, effective April 14, 2023.

Latest news about NKGen Biotech, Inc.

Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	Apr. 29	CI
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	Apr. 28	CI
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	Apr. 18	CI
NKGen Biotech, Inc. announced that it has received $5 million in funding	Apr. 04	CI
NKGen Biotech, Inc. announced that it has received $0.5 million in funding from AJB Capital Investments LLC, Sandia Investment Managment LP, Diametric Capital, LP	Mar. 31	CI
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	Mar. 25	CI
NKGen Biotech, Inc. announced that it expects to receive $0.33 million in funding from FirstFire Capital Management LLC	Mar. 20	CI
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board	Mar. 20	CI
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee	Feb. 08	CI
Exchange-Traded Funds Lower, Equity Futures Flat Pre-Bell Friday	Dec. 29	MT
NKGen Biotech Doses First Patient in Clinical Trial for Alzheimer's Disease Therapy	Dec. 29	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Dec. 29	MT
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease	Dec. 28	CI
NKGen Biotech Gets Canadian Regulator's Clearance to Study NK Cell Therapy for Alzheimer's	Dec. 27	MT
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	Dec. 27	CI
NKGen Biotech, Inc.(NasdaqGM:NKGN) added to S&P TMI Index	Dec. 18	CI
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast	23-10-27	MT
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports	23-10-27	MT
Top Premarket Gainers	23-10-27	MT
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease Conference	23-10-26	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	23-10-24	MT
NKGen Biotech Gets FDA Clearance to Start Alzheimer's Disease Trial; Shares Jump	23-10-24	MT
NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01	23-10-24	DJ
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	23-10-24	CI
NKGen Biotech, Inc.(NasdaqGM:NKGN) added to NASDAQ Composite Index	23-10-04	CI

NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimerâs disease (AD) and Parkinsonâs disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - American Society of Clinical Oncology Annual Meeting - e14515

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NKGEN BIOTECH, INC.	-83.86%	30.56M
MODERNA, INC.	+22.81%	46.81B
LONZA GROUP AG	+47.13%	41.29B
IQVIA HOLDINGS INC.	-1.88%	41.37B
CELLTRION, INC.	-6.20%	28.87B
ICON PUBLIC LIMITED COMPANY	+11.33%	26.06B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	-1.43%	11.96B
MEDPACE HOLDINGS, INC.	+30.73%	12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	12.08B

Other Biotechnology & Medical Research

NKGen Biotech, Inc. Nyse

Equities

NKGN

US65488A1016

Biotechnology & Medical Research

Graf Acquisition Corp. IV Announces Resignation of Sterling Cross as Chief Financial Officer

Latest news about NKGen Biotech, Inc.

Chart NKGen Biotech, Inc.

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research